Euroapi (EAPI) AGM 2025 summary

Opening remarks and agenda

• The AGM was opened by the chairman, with board members, management, and auditors present; safety and procedural details were reviewed, and the agenda included 15 ordinary and 16 extraordinary resolutions.

• Notices were duly published and sent to shareholders, with 78.7% of capital represented, ensuring valid proceedings.

• Governance roadshows held in April-May 2025 to engage stakeholders and present governance updates.

Financial performance review

• 2024 revenue was EUR 911.9 million, down 10% from 2023, with core EBITDA at EUR 50.4 million (5.5% margin), a 45.8% decrease.

• Net loss for 2024 was EUR 130.6 million, improved from EUR 189 million in 2023; net cash position at year-end was EUR 25.2 million, reversing prior net debt.

• Industrial CapEx reached EUR 128 million, with 53% for growth/performance projects; working capital improved by EUR 100 million.

• Approval of parent company and consolidated financial statements for the year ended December 31, 2024.

• Allocation of loss for the financial year ended December 31, 2024.

Strategic initiatives and plans

• The Focus 27 plan advanced across four pillars: portfolio rationalization, targeted CDMO offering, industrial footprint streamlining, and organizational transformation.

• Board reviewed and monitored the FOCUS-27 strategic plan, including industrial footprint adjustments and ESG commitments.

• CEO variable remuneration for 2025 tied to FOCUS-27 execution, free cash flow, EBITDA margin, and ESG targets.

• Sanofi invested EUR 200 million in hybrid bonds and reserved production capacity, supporting refinancing and future growth.

• ESG initiatives accelerated, including decarbonization targets and SBTI commitment; solvent recycling and emissions reductions achieved.